Brief: Sellas Announces Positive Topline Data In Lymphoma Cohort From Sls009 Phase 1 Dose-Escalation Trial

Sellas Life Sciences

21/09/2023 13:48

Sept 21 (Reuters) - Sellas Life Sciences Group Inc
 SLS.O :
    * SELLAS ANNOUNCES POSITIVE TOPLINE DATA IN LYMPHOMA COHORT
FROM
SLS009 PHASE 1 DOSE-ESCALATION TRIAL, SUPPORTING ADVANCEMENT TO
PHASE 2 CLINICAL STUDY; PRIMARY AND SECONDARY ENDPOINTS MET
    * SELLAS ANNOUNCES POSITIVE TOPLINE DATA IN LYMPHOMA COHORT
FROM
SLS009 PHASE 1 DOSE-ESCALATION TRIAL, SUPPORTING ADVANCEMENT TO
PHASE 2 CLINICAL STUDY; PRIMARY AND SECONDARY ENDPOINTS MET
    * SELLAS LIFE SCIENCES GROUP INC - RECOMMENDED PHASE 2 DOSE
FOR
LYMPHOMA PATIENTS ESTABLISHED AT 100 MG ONCE PER WEEK
    * SELLAS LIFE SCIENCES GROUP INC: STUDY SHOWED NO OFF-TARGET
SAFETY ISSUES AT ANY DOSE LEVEL
    * SELLAS LIFE SCIENCES GROUP INC: THERE WERE NO DRUG-RELATED
FATALITIES AT ANY DOSE LEVEL, AND DRUG WAS WELL TOLERATED

Source text for Eikon:  ID:nGNX8k6DJm 
Further company coverage:  SLS.O 

 ((Reuters.Briefs@thomsonreuters.com))